Prescient Therapeutics provides PTX-100 trial update, readies for investor briefing
Since the last trial update, a patient with relapsed peripheral T cell lymphoma reported a...
Since the last trial update, a patient with relapsed peripheral T cell lymphoma reported a...
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the...
Prescient Therapeutics Ltd (ASX:PTX) continues to demonstrate a favourable safety profile with its PTX-100 Phase 1b expansion...
“It is very exciting to see PTX-100 show clinical activity in a patient population that...
Prescient Therapeutics Ltd (ASX:PTX) has brought in another A$2.5 million in a top-up placement to cater...
“It is a significant achievement to exceed our target amidst challenging market conditions,” said managing...
CellPryme-A is the latest in a portfolio of platform cell technologies that can not only...
Prescient Therapeutics Ltd (ASX:PTX) has been invited to present two sessions at the upcoming CAR-TCR Summit...
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the...
"We believe that OmniCAR is a transformational platform for cellular immunotherapy, and we look forward...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.